← Shanghai Haoyuan Chemexpress Co. Ltd. A overview

Shanghai Haoyuan Chemexpress Co. Ltd. A vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Haoyuan Chemexpress Co. Ltd. A (688131.CG)

Q3 202629 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

August 202629 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Latest29 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Avantor Inc (AVTR)

Q3 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

August 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest13 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.